Aptose Biosciences (NASDAQ:APTO) Given “Buy” Rating at HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $2.00 price target on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of Aptose Biosciences in a research report on Wednesday. They issued a “hold” rating on the stock.

Aptose Biosciences Stock Down 6.2 %

NASDAQ APTO opened at $0.21 on Friday. The firm has a market capitalization of $12.83 million, a PE ratio of -0.07 and a beta of 0.87. The stock’s 50 day moving average is $0.25 and its 200 day moving average is $0.41. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.